<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=KML_29</id>
	<title>KML 29 - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.com/index.php?action=history&amp;feed=atom&amp;title=KML_29"/>
	<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=KML_29&amp;action=history"/>
	<updated>2026-04-11T02:49:51Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.com/index.php?title=KML_29&amp;diff=6023018&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.com/index.php?title=KML_29&amp;diff=6023018&amp;oldid=prev"/>
		<updated>2024-12-02T03:29:56Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;KML 29&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;KML 29&amp;#039;&amp;#039;&amp;#039; is a chemical compound that has been studied for its potential therapeutic effects, particularly in the field of [[neuroscience]]. It is known to interact with the [[endocannabinoid system]], which plays a crucial role in regulating various physiological processes such as mood, appetite, and pain sensation.&lt;br /&gt;
&lt;br /&gt;
==Chemical Structure and Properties==&lt;br /&gt;
KML 29 is classified as a [[selective inhibitor]] of the enzyme [[monoacylglycerol lipase]] (MAGL). This enzyme is responsible for the breakdown of the endocannabinoid [[2-arachidonoylglycerol]] (2-AG), which is a major ligand for the [[cannabinoid receptors]] CB1 and CB2.&lt;br /&gt;
&lt;br /&gt;
The chemical structure of KML 29 allows it to bind effectively to the active site of MAGL, thereby inhibiting its activity. This inhibition leads to increased levels of 2-AG in the brain, which can enhance cannabinoid receptor signaling.&lt;br /&gt;
&lt;br /&gt;
==Pharmacological Effects==&lt;br /&gt;
By inhibiting MAGL, KML 29 increases the concentration of 2-AG, which can result in various pharmacological effects:&lt;br /&gt;
&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Analgesic Effects&amp;#039;&amp;#039;&amp;#039;: KML 29 has been shown to reduce pain in animal models, suggesting its potential use as an analgesic agent.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Anti-inflammatory Effects&amp;#039;&amp;#039;&amp;#039;: The compound may also exhibit anti-inflammatory properties by modulating the endocannabinoid system.&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Neuroprotective Effects&amp;#039;&amp;#039;&amp;#039;: There is evidence to suggest that KML 29 could have neuroprotective effects, making it a candidate for the treatment of neurodegenerative diseases.&lt;br /&gt;
&lt;br /&gt;
==Research and Development==&lt;br /&gt;
Research on KML 29 is ongoing, with studies focusing on its potential therapeutic applications and safety profile. Preclinical studies have demonstrated promising results, but further research is needed to fully understand its effects and potential side effects.&lt;br /&gt;
&lt;br /&gt;
==Potential Therapeutic Applications==&lt;br /&gt;
KML 29 is being investigated for its potential use in treating various conditions, including:&lt;br /&gt;
&lt;br /&gt;
* [[Chronic pain]]&lt;br /&gt;
* [[Inflammatory diseases]]&lt;br /&gt;
* [[Neurodegenerative disorders]] such as [[Alzheimer&amp;#039;s disease]] and [[Parkinson&amp;#039;s disease]]&lt;br /&gt;
&lt;br /&gt;
==Safety and Side Effects==&lt;br /&gt;
As with any pharmacological agent, the safety profile of KML 29 is an important consideration. Studies are being conducted to assess its toxicity, potential side effects, and long-term safety in humans.&lt;br /&gt;
&lt;br /&gt;
==Also see==&lt;br /&gt;
* [[Endocannabinoid system]]&lt;br /&gt;
* [[Monoacylglycerol lipase]]&lt;br /&gt;
* [[Cannabinoid receptors]]&lt;br /&gt;
* [[2-arachidonoylglycerol]]&lt;br /&gt;
&lt;br /&gt;
{{Pharmacology}}&lt;br /&gt;
{{Neuroscience}}&lt;br /&gt;
&lt;br /&gt;
[[Category:Pharmacology]]&lt;br /&gt;
[[Category:Neuroscience]]&lt;br /&gt;
[[Category:Endocannabinoid system]]&lt;/div&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
</feed>